Notably, cetuximab and panitumumab have not significantly affected survival rates in CRC with KRAS exon 2 activating mutations, indicating that the efficacy of EGFR inhibitors is primarily observed in KRAS wild‐type CRC [203]. Here, KRAS is linked to colorectal carcinoma.